Pharma & Biotech - Page 10

President Donald Trump has named Heidi Overton as his pick for the next commissioner of the Food and Drug Administration, ending three months without a permanent leader. Overton, who holds both an

Lucid Group, a healthcare communications and commercialisation agency, has appointed Eric Muller as its new chief executive officer. Muller joins from Publicis Health, where he held the position of Group President and

Novo Nordisk is pushing forward with a new late-stage clinical study testing smaller doses of its oral semaglutide obesity treatment, known as the Wegovy pill. The OASIS 5 trial launched just eight

Eli Lilly’s once-weekly injectable insulin, Onswik, has received a positive recommendation from the UK’s drug cost watchdog, moving it closer to NHS availability for type 2 diabetes patients. The National Institute for

China’s investigator-initiated trials, once celebrated for accelerating the country’s biotech boom, are now facing serious international scrutiny over transparency failures. The controversy began after several previously undisclosed deaths were uncovered within weeks,

The latest round of Big Pharma earnings calls delivered a sweeping look at the opportunities and challenges shaping the biopharma industry heading into the second half of 2026. Quarterly earnings seasons have

Lundbeck’s chief executive Charl van Zyl says the Danish neuroscience company is firmly on track to keep “punching above its weight” as a mid-cap challenger in the sector. The company posted sales

B. Braun Medical has initiated a recall of a single lot of Excel lactated ringers injection across the United States and Canada due to particulate contamination concerns. The recall affects product shipped

Regeneron Pharmaceuticals (REGN) has launched a five-episode video podcast series designed to transform complex scientific concepts into a calming, immersive audio-visual journey. The series, titled “Science Illuminated,” debuted on August 3 on

Xspray Pharma has received yet another Complete Response Letter from the U.S. Food and Drug Administration, further delaying approval of its leukemia drug candidate Dasynoc. The setback marks the latest in a